2. Signaling Pathways
  3. GPCR/G Protein
  4. LPL Receptor
  5. LPAR3 Isoform

LPAR3

 

LPAR3 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-15706
    H2L 5765834
    		Antagonist 98.66%
    H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA1, LPA3, and LPA5, with IC50s of 94, 752, and 463 nM respectively.
  • HY-178845
    Decyl phosphate
    		Modulator
    Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders.
  • HY-148291
    BrP-LPA sodium
    		Antagonist
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.
  • HY-W725737
    BrP-LPA
    		Antagonist
    BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior.